Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Methylphenidate
Drug ID BADD_D01431
Description Methylphenidate is a central nervous system stimulant used most commonly in the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) and for narcolepsy. Also known as the marketed products Ritalin, Concerta, or Biphentin, methylphenidate is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve the following group of developmentally inappropriate symptoms associated with ADHD: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. Long-acting formulations of psychostimulants such as methylphenidate, [DB01576], and [DB01255] are considered the most effective and widely used treatment for ADHD, and are considered first-line options for children, adolescents, and adults as recommended by CADDRA (Canadian ADHD Resource Alliance). [L6037] CADDRA recommends the use of methylphenidate due to long term studies, of over twenty years in duration, which show methylphenidate is safe and effective.
Indications and Usage For use as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity.
Marketing Status Prescription; Discontinued
ATC Code N06BA04
DrugBank ID DB00422
KEGG ID D04999
MeSH ID D008774
PubChem ID 4158
TTD Drug ID D02PPN
NDC Product Code 70165-200; 68968-5554; 0406-7654; 0781-2361; 0781-2364; 68968-5553; 68968-5555; 70165-100; 70165-300; 68968-5552; 0781-2363; 0781-2362
Synonyms Methylphenidate | Metadate | Equasym | Methylin | Concerta | Phenidylate | Ritalin | Ritaline | Ritalin-SR | Ritalin SR | Tsentedrin | Centedrin | Daytrana | Methylphenidate Hydrochloride | Hydrochloride, Methylphenidate
Chemical Information
Molecular Formula C14H19NO2
CAS Registry Number 113-45-1
SMILES COC(=O)C(C1CCCCN1)C2=CC=CC=C2
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
HepatotoxicityBeta-2 adrenergic receptorP07550T525229187524; 7913199; 8382844; 6147001; 1957308; 7716792; 12616289
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Cough22.02.03.001--
Crohn's disease10.02.01.005; 07.08.01.0150.000643%Not Available
Crying17.02.05.013; 19.04.02.002; 12.02.11.001; 08.01.03.0050.003948%Not Available
Cyanosis24.03.01.007; 22.02.02.007; 02.01.02.0020.000459%
Deafness04.02.01.0010.000551%Not Available
Death08.04.01.001--
Decreased activity19.11.01.002; 08.01.01.0060.000184%Not Available
Decreased interest19.15.02.0040.000184%Not Available
Dehydration14.05.05.001--
Delayed puberty21.03.02.014; 05.05.03.0030.000367%
Delirium19.13.02.0010.000826%
Delusion19.10.01.0010.001561%
Dental caries07.09.01.0010.000275%
Dependence19.07.02.0030.000367%Not Available
Depressed level of consciousness17.02.04.0020.001010%
Depressed mood19.15.02.0010.002112%Not Available
Depression19.15.01.0010.005968%
Dermatitis23.03.04.002--Not Available
Dermatitis allergic23.03.04.003; 10.01.03.0140.000184%Not Available
Dermatitis bullous23.03.01.0020.000184%
Dermatitis contact12.03.01.040; 10.01.01.003; 23.03.04.0040.000275%Not Available
Dermatitis exfoliative23.03.07.001; 10.01.01.0040.000184%
Diabetes mellitus14.06.01.001; 05.06.01.001--Not Available
Diarrhoea07.02.01.001--
Dilatation ventricular02.04.02.0260.000048%Not Available
Diplopia17.17.01.005; 06.02.06.0020.000643%Not Available
Discomfort08.01.08.0030.000735%Not Available
Disinhibition19.05.01.0020.000184%Not Available
Disorientation19.13.01.002; 17.02.05.0150.000826%Not Available
Dissociation19.14.01.0020.000184%Not Available
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 27 Pages